The Alliance for Regenerative Medicine (ARM)'s mission is to advance regenerative medicine by representing, supporting and engaging all stakeholders in the field, including companies, academic research institutions, patient advocacy groups, foundations, health insurers, financial institutions and other organizations.
Based in Washington, D.C., ARM is a global advocacy organization that promotes legislative, regulatory, reimbursement, investment, technical and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understanding of the field and its potential to transform human healthcare.
Athersys Inc. is a clinical-stage biotechnology company developing MultiStem, a patented, adult-derived "off-the-shelf" stem cell product platform for the cardiovascular, neurological, inflammatory and immune disease areas. More
BioLife Solutions Inc. develops, manufactures and markets hypothermic storage and cryopreservation freeze media products for cells, tissues and organs. More
BrainStorm Cell Therapeutics Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. More
Caladrius Biosciences Inc. (formerly NeoStem Inc.) is an international biopharmaceutical company. The company operates in three segments: Cell therapy (United States), regenerative medicine (China) and pharmaceutical manufacturing (China). More
Cesca Therapeutics Inc. is a fully integrated regenerative medicine company that combines cell-therapy-related devices, patented platform technology, and proprietary cell formulations and treatment protocols for the development of commercializable cell therapies. More
Cynata Therapeutics Ltd. is an Australian stem cell and regenerative medicine company that is developing Cymerus, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison. More
Cytori Therapeutics Inc. is a cell therapy company dedicated primarily to the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. More
Mesoblast Ltd. is a clinical development company leveraging its proprietary core adult stem cell technologies, which include the Mesenchymal Precursor Cell (MPC) and culture-expanded Mesenchymal Stem Cell (MSC) platform technologies, Dental Pulp Stem Cells and expanded Hematopoietic Stem Cells. More
Pluristem Therapeutics Inc. is a biotechnology company that is developing off-the-shelf cell therapies for a variety of human diseases. More
RepliCel Life Sciences Inc. is a regenerative medicine company developing autologous cell therapies that treat functional cellular deficits utilizing cells isolated from a patient's own healthy hair follicles. More
StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. More
|"VIVs recent distribution deals illustrate demand for its technology."|
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"DRRX intends to start a NASH trial as soon as H1/19."|